Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in ...
The firm’s CEO cited a “very competitive” recruiting market in 2024, but forecasts a better 2025 as longer-term efforts pay ...
Stifel chief executive Ron Kruszewski said surging markets have forced firms to be particularly choosy about which advisors ...
Stifel Nicolaus analyst Ian Gillies maintained a Buy rating on Badger Infrastructure Solutions (BADFF – Research Report) today and set a price ...
Barry Bannister, Stifel chief equity strategist, joins 'Power Lunch' to discuss the bad signs for the market and the DeepSeek ...
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $125.6, a high estimate of $135.00, and a low estimate of $115.00. This upward trend is evident, ...
Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...
After the market closed yesterday, Stifel published new coverage on Datadog. The firm downgraded its rating on the stock from ...